Prof. Charles Craddock | Ravva Study: Molecular Predictors Of Response To Azacytidine

Prof. Charles Craddock | RAvVA study: molecular predictors of response to azacytidine

Azacitidine/HDAC inhibitor combination for high risk AML: a promising pilot study

VJHemOnc – Video Journal of Hematology & HemOnc

Professor Charlie Craddock on his CBE

What steps should a patient take after being diagnosed with leukemia?

The Patients' Channel

Professor Charlie Craddock CBE

Prof Charles Craddock The emerging role of maintenance therapies

2nd. Leukemia symposium KFSHRC Jeddah

Prof. C Craddock | EBMT 2018 | Can hypomethylating agents prevent post-transplant relapse in AML?

Prof. Charles Craddock- Genetic landscape of AML and its relevance to treatment

2nd. Leukemia symposium KFSHRC Jeddah

Professor Charlie Craddock discusses Cure Leukaemia

From the bench to bedside: AML treatment

VJHemOnc – Video Journal of Hematology & HemOnc

Results of the RAvVA trial of azacitidine with or without vorinostat in AML

VJHemOnc – Video Journal of Hematology & HemOnc

Charles Craddock interview (subtitled)

British Society for Haematology

Transplantation and Acute Myeloid Leukaemia - Prof. Charles Craddock

The Sri Lanka College of Oncologists

#DBTechHackathon - Professor Charlie Craddock CBE

ASM 2018 - Professor Charles Craddock

British Society for Haematology

Professor Charlie Craddock CBE on Carl Ikeme's diagnosis

Recent developments in the mutational landscape and molecular basis of AML

VJHemOnc – Video Journal of Hematology & HemOnc

Our co-founder Professor Charlie Craddock CBE discusses Mark's treatment for CML

The importance of detecting MRD in the treatment of AML

VJHemOnc – Video Journal of Hematology & HemOnc

Professor Charlie Craddock CBE with a message for Deutsche Bank